Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.

European journal of cancer (Oxford, England : 1990) - 1 Jan 2018

Schaper-Gerhardt Katrin, Okoye Steven, Herbst Rudolf, Ulrich Jens, Terheyden Patrick, Pföhler Claudia, Utikal Jochen S, Kreuter Alexander, Mohr Peter, Dippel Edgar, Satzger Imke, Sucker Antje, Schadendorf Dirk, Ugurel Selma, Gutzmer Ralf

Abstract excerpt

BACKGROUND: Targeted therapies with BRAF plus MEK inhibitors (BRAFi; MEKi) represent the major treatment strategy for patients with BRAF-mutated metastatic melanoma (MM). Previous analyses suggested a correlation between programmed death-ligand 1 (PD-L1) expression in tumour tissues and the outcome of targeted therapies. This study investigated PD-L1 as a potential predictive biomarker of BRAFi-based targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Indoles

Share to Kaplan-Meier Estimate

Share to Oximes

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 29195116
DOI: 10.1016/j.ejca.2017.10.026

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.PMID 29195116Read ↗

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Semantic proximity Read ↗

PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.Semantic proximity Read ↗

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.Semantic proximity Read ↗

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.Semantic proximity Read ↗

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.Semantic proximity Read ↗

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.Semantic proximity Read ↗

Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.Semantic proximity Read ↗

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.Semantic proximity Read ↗

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.